Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients

2013 ◽  
Vol 51 (2) ◽  
Author(s):  
Benjamin Nisman ◽  
Tanir Allweis ◽  
Luna Kadouri ◽  
Bela Mali ◽  
Tamar Hamburger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Thymidine Kinase ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Thymidine Kinase 1 ◽  
Prognostic Performance

scholarly journals Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes

2020 ◽  
Vol 40 (4) ◽  
Author(s):  
Zhiwu Wang ◽  
Wei Zhang ◽  
Bingjie Huo ◽  
Liang Dong ◽  
Jing Zhang
Keyword(s):  
Breast Cancer ◽  
Thymidine Kinase ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Univariate Analysis ◽  
Clinical Parameters ◽  
Breast Cancer Patients ◽  
Thymidine Kinase 1 ◽  
Node Number ◽  
Significant Difference

Abstract In a retrospective study design, we explored the relationship between serum thymidine kinase 1 (TK1) concentration before radiotherapy and clinical parameters and evaluated the prognostic value of serum TK1 concentration before radiotherapy in breast cancer patients with type 2 diabetes mellitus. The present study finally consisted of 428 breast cancer patients with a mean age of 53.0 years. Compared with low TK1 group, the high TK1 group tended to have larger tumor size (P=0.011) and had more lymph node number (P=0.021). Significant differences were also observed in clinical stages I, II and III (P=0.000). There was no significant difference between TK1 and other clinical parameters. For disease-free survival (DFS), the univariate analysis indicated that the high TK1 increased the risk of poor prognosis (HR = 2.38, 95% CI: 1.64–4.23, P=0.000). The Kaplan–Meier curve indicated the high TK1 group was poorer than that in the low TK1 group (P=0.002). For the overall survival (OS), similar results were found that the high TK1 was related to poor OS (HR = 1.89, 95% CI: 1.34–3.67, P=0.000). The multivariate Cox regression indicated that the TK1 was still associated with DFS (HR = 1.83, 95% CI: 1.22–3.17, P=0.001) and OS (HR = 1.63, 95% CI: 1.19–2.08, P=0.006). The high pretreatment serum TK1 levels in breast cancer patients were associated with poor OS and DFS. TK1 could be a potential predictive factor in differential diagnosis of poor prognosis from all patients.

scholarly journals The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

2016 ◽  
Vol 115 (12) ◽  
pp. 1471-1478 ◽  
Author(s):  
Matteo Lambertini ◽  
Ana Catarina Pinto ◽  
Lieveke Ameye ◽  
Lynn Jongen ◽  
Lucia Del Mastro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Index ◽  
Nottingham Prognostic Index ◽  
Breast Cancer Patients ◽  
Prognostic Performance ◽  
Young Breast Cancer

scholarly journals Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients

2021 ◽  
Vol 10 (22) ◽  
pp. 5416
Author(s):  
Giuseppe Nicolò Fanelli ◽  
Rosa Scarpitta ◽  
Paola Cinacchi ◽  
Beatrice Fuochi ◽  
Anna Szumera-Ciećkiewicz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Thymidine Kinase ◽  
Histological Grade ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Thymidine Kinase 1 ◽  
Ki 67 ◽  
Pyrimidine Nucleotide ◽  
Prognostic Stratification ◽  
The Impact

Breast cancer (BC) is the most frequent non-cutaneous malignancy in women. Histological grade, expression of estrogen and progesterone receptors (ER and PgR), overexpression/amplification of the human epidermal growth factor receptor 2 (HER2) oncogene, and proliferative activity measured with ki-67 provide important information on the biological features of BC and guide treatment choices. However, a biomarker that allows a more accurate prognostic stratification is still lacking. Thymidine kinase-1 (TK1), a ubiquitous enzyme involved in the pyrimidine nucleotide recovery pathway, is a cell-proliferation marker with potential prognostic and predictive impacts in BC. Eighty (80) cases of invasive BC with a long-term follow-up were retrospectively selected, and clinicopathological data were collected for each patient. TK1 tissue expression was evaluated immunohistochemically. Data suggested that TK1 expression levels are positively correlated with ER and PgR expression, and negatively correlated with HER2 status and the impact on patients' distant recurrence-free survival (DRFS): in detail, among patients undergoing adjuvant chemotherapy, lower TK1 levels are correlated with better DRFS. Therefore, these results contribute to furthering the knowledge of TK1, suggesting a possible and important role of this enzyme as a biomarker in the stratification of BC patients.

The Clinical Significance of Thymidine Kinase 1 Measurement in Serum of Breast Cancer Patients Using Anti-TK1 Antibody

2000 ◽  
Vol 15 (2) ◽  
pp. 139-146 ◽  
Author(s):  
Q. He ◽  
L. Zou ◽  
P.A. Zhang ◽  
J.X. Lui ◽  
S. Skog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Healthy Volunteers ◽  
Thymidine Kinase ◽  
Cancer Patients ◽  
Polyclonal Antibodies ◽  
Benign Tumors ◽  
Breast Cancer Patients ◽  
Dot Blot ◽  
Significant Difference ◽  
Dot Blot Assay

The activity of total thymidine kinase in serum (S-TK) has been used as a tumor maker for decades. To date such activity has been determined using [125]I-iodo-deoxyuridine as a substrate. The aim of this study was to develop a new, antibody-based technique for the measurement of cytoplasmic thymidine kinase (TK1) in serum. Both mono- and polyclonal antibodies against S-TK1 were used in dot blot assay. S-TK1 was characterized by SDS and IEF techniques. Sixty-five breast cancer patients were studied, including 17 preoperative and 38 postoperative tumor-free patients and 10 patients with metastases to the lymph nodes (N1–2). They were compared to patients with benign tumors (n=21) and healthy volunteers (n=11). S-TK1 was low (0–1.0 pM) in healthy volunteers, while in preoperative patients the level was increased 6–110-fold. Significant differences were observed between preoperative patients and healthy volunteers (p=0.005), preoperative patients and patients with benign tumors (p<0.001), and preoperative patients and postoperative patients without metastases (p<0.001). No significant difference was observed between preoperative patients and postoperative patients with metastases (p=0.191). The S-TK activity in preoperative patients was also high in serum, but no decrease was observed following surgery. In conclusion, the anti-TK1 antibody could be a good marker for monitoring the response of breast cancer patients to therapy.

Sign in / Sign up

Export Citation Format

Share Document